PMS (postmarket surveillance) key focus in CDRH (Center for Devices and Radiological Health) guidance document plans
This article was originally published in Clinica
Executive Summary
Based on its list of guidance documents under development, the FDA's device centre (CDRH) has charted an ambitious workplan over the next 12 months. Most of the items included in the agency's annual guidance document agenda published yesterday are highly product specific.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.